Home > Insider Trading > Filing (0001104659-15-049011)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1454789	Catabasis Pharmaceuticals Inc	CATB	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1645130	Ron Laufer	C/O Medimmune Ventures, Inc. One Medimmune Way Gaithersburg MD 20878		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-06-30	1,079,115	$0.00	1,079,115	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2015-06-30	330,098	$0.00	1,409,213	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2015-06-30	223,439	$12.00	1,632,652	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2015-06-30	13,866,666	$0.00	1,079,115	$0.00
Common Stock	Series B Preferred Stock	Disposition	2015-06-30	4,241,780	$0.00	330,098	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2015-06-30	11,094	$0.00	11,094	$12.21

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
11,094	2025-06-29	No	4	A	Direct

Footnotes

The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by MedImmune Ventures, Inc. Dr. Laufer is the Senior Managing Partner of MedImmune Ventures, Inc., and as a result, Dr. Laufer may be deemed to hold voting, dispositive and investment power over the shares held by MedImmune Ventures, Inc. Dr. Laufer disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
This option was granted on June 30, 2015 and vests over three years, with one-third of the shares vesting on each anniversary of the grant date until the third anniversary of the grant date.